Acura Pharmaceuticals, Inc.: reports $11,294,279 secured note balance

What happened Acura Pharmaceuticals, Inc. filed an 8-K reporting that on Sep 18, 2026 and Oct 2, 2026 it received a $100,000 loan on each date from Abuse Deterrent Pharma, LLC. The filing states that, combined with previous loans and $2,319,279 under the Nov 10, 2022 amended consolidated and restated secured promissory note, the Note now has a principal balance of $11,294,279 with accrued interest of approximately $1,365,000 as of Sep 30, 2026 and bears interest at 5.25%.

Key details

• lender: Abuse Deterrent Pharma, LLC; loans received Sep 18, 2026 and Oct 2, 2026 of $100,000 each.
• principal balance: $11,294,279; accrued interest: approximately $1,365,000 as of Sep 30, 2026.
• interest rate: 5.25% per annum; overdue amounts bear interest at 7.5% per annum from date of non-payment.
• events of default include bankruptcy events, failure to pay interest or principal when due (and such failure continues for 5 days), and inability to pay debts as they become due.
• filing states the funding was used to meet day-to-day operations and that, in the absence of additional financing by mid-Oct 2026, the company may be required to scale back operations, including furloughs and lay-offs, or to terminate operations and/or seek bankruptcy protection, which could result in a complete loss of shareholder value.

Why it may matter The filing reports Item 1.01 (entry into a material definitive agreement) and Item 2.03 (creation of a direct financial obligation), describing the amended loan schedule and the terms of the secured promissory note with Abuse Deterrent Pharma, LLC. A filing does not show why the insider traded or why the company acted.